Indocyanine Green (ICG) Guided Sentinel Lymph Node Mapping for Pediatric Visceral Solid Tumors
Part of paid clinical trials in Chicago, Illinois.
- Sponsor
- St. Jude Children's Research Hospital
- Study ID
- NCT05645523
- Phase
- EARLY_PHASE1
- Status
- Recruiting
Conditions
- Solid Tumor
Eligibility Criteria
- Sex
- ALL
- Age
- N/A - 20 Years
- Healthy Volunteers
- Not accepted
Interventions
- Indocyanine Green — DRUGGiven in to the vein (IV)
Study Details
The purpose of the study is to find out the usefulness and safety of a dye called Indocyanine Green (ICG for short). This dye will be used to help the surgeon find lymph nodes draining solid tumors inside the abdomen that need to be removed. This may also help the surgeon to find if the cancer has moved to other lymph nodes outside of the known area. Primary Objectives * To determine the percentage of patients in whom Indocyanine Green (ICG)-guided sentinel lymph node (SLN) mapping was successful at the time of retroperitoneal lymph node dissection for staging of visceral solid tumors. * To determine the percentage of patients with grade 3 or higher adverse events related to ICG use.
Key Dates
- Start date
- Oct 24, 2023
- Status verified
- May 2026
- Primary completion
- Dec 31, 2026
- Completion
- Dec 31, 2026
Study Design
- Enrollment
- 25 participants (estimated)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- DIAGNOSTIC
Arms
- Experimental: Indocyanine green (ICG)Participants will receive Indocyanine green intraoperatively.
Primary Outcome Measure
Percentage of patients in whom Indocyanine Green (ICG)-guided sentinel lymph node (SLN) mapping was successful [ Time Frame: During surgery (Intraoperatively) ]
Central Contacts
- Andrew Davidoff, MD888-226-4343
Locations (3)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Lurie Children's Hospital | Chicago | Illinois | 60611 | Timothy Lautz, MD (PRINCIPAL_INVESTIGATOR) |
| Children's Hospital of Pittsburgh of UPMC | Pittsburgh | Pennsylvania | 15224 | Marcus Malek, MD (PRINCIPAL_INVESTIGATOR) |
| St. Jude Children's Research Hospital | Memphis | Tennessee | 38105 | Andrew Davidoff, MD (PRINCIPAL_INVESTIGATOR) |
Find similar trials in Chicago, IL
Related Studies
- A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)PHASE1/PHASE2 · Recruiting · Merck Sharp & Dohme LLC · Aurora, Colorado
- Safety and Preliminary Efficacy of OBT076 in Recurrent/Metastatic CD205+ Solid TumorsPHASE1 · Recruiting · Oxford BioTherapeutics Ltd · Phoenix, Arizona
- Indocyanine Green (ICG) Guided Tumor ResectionPHASE1 · Recruiting · St. Jude Children's Research Hospital · Memphis, Tennessee
- Study of Induction PD-1 Blockade in Subjects With Locally Advanced Mismatch Repair Deficient Solid TumorsPHASE2 · Recruiting · Memorial Sloan Kettering Cancer Center · Hartford, Connecticut